These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26869769)

  • 1. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
    Xu Z; Fan C; Zhao X; Tao H
    Drug Des Devel Ther; 2016; 10():509-17. PubMed ID: 26869769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
    Cui L; Xia W; Yu C; Dong S; Pei Y
    Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eldecalcitol: a review of its use in the treatment of osteoporosis.
    Sanford M; McCormack PL
    Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Smith SY; Doyle N; Boyer M; Chouinard L; Saito H
    Bone; 2013 Nov; 57(1):116-22. PubMed ID: 23774444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone.
    Saito M; Grynpas MD; Burr DB; Allen MR; Smith SY; Doyle N; Amizuka N; Hasegawa T; Kida Y; Marumo K; Saito H
    Bone; 2015 Apr; 73():8-15. PubMed ID: 25482210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
    Sugimoto M; Futaki N; Harada M; Kaku S
    Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eldecalcitol, an Active Vitamin D
    Takeda S; Saito M; Sakai S; Yogo K; Marumo K; Endo K
    Calcif Tissue Int; 2017 Oct; 101(4):433-444. PubMed ID: 28624935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eldecalcitol for the treatment of osteoporosis.
    Matsumoto T; Endo I
    Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.
    Ito M; Nakamura T; Fukunaga M; Shiraki M; Matsumoto T
    Bone; 2011 Sep; 49(3):328-34. PubMed ID: 21605716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis.
    Zheng Z; Luo J
    J Orthop Surg Res; 2020 Sep; 15(1):390. PubMed ID: 32907639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.
    Shiraki M; Saito H; Matsumoto T
    Curr Med Res Opin; 2012 Sep; 28(9):1547-52. PubMed ID: 22794117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Liu H; Wang G; Wu T; Mu Y; Gu W
    Front Endocrinol (Lausanne); 2022; 13():854439. PubMed ID: 35518938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
    Takeda S; Sakai S; Shiraishi A; Koike N; Mihara M; Endo K
    Bone; 2013 Mar; 53(1):167-73. PubMed ID: 23232307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.